throbber
9/18/2019
`
`Financial Support Info | Tecfidera® (dimethyl fumarate)
`
`Important Safety Information
`
`Patient Information & Prescribing Information
`
`Financial & insurance information
`Get financial & insurance support for your relapsing multiple sclerosis (MS) treatment
`Above MS Support Coordinators can help you understand your insurance coverage and try to identify the best financial assistance solution
`for you. Our goal is for no one to forgo treatment based solely on financial limitations.
`
`Financial and insurance services include:
`Benefits investigation to clarify your coverage options
`Insurance counseling including help navigating changes due to the healthcare reform law
`$0 Copay Program with no income requirements and no enrollment time limit for those who are eligible.* Call 1-800-456-2255 to see if
`you’re eligible
`Free drug program for eligible patients in need 
`Support finding assistance through charitable organizations
`
`To learn more about the financial services offered, call one of our Support Coordinators at 1-800-456-2255, Monday
`through Friday, 8:30 AM to 8 PM ET. Support is available in Spanish.
`
`*Depending on your income or, in some cases, if your medication is obtained from an out-of-network provider, there may be an annual cap
`that limits the amount of assistance that you can receive over one year. Federal and state laws and other factors may prevent or otherwise
`restrict eligibility. People covered by Medicare, Medicaid, the VA/DoD, or any other federal plans are not eligible to enroll. You are eligible to
`enroll in the $0 Copay Program for as long as you are treated with a Biogen relapsing MS medication.
`
`We also recommend
`
`Sign up for personalized support for MS
`
`Find an event near you or online
`
`Get tips, tools & more with Above MS
`
`NEXT: Find an event ❯
`
`IMPORTANT SAFETY INFORMATION
`Do not use Tecfidera (dimethyl fumarate) if you have had an allergic reaction (such as welts, hives, swelling of the face, lips, mouth or

`tongue, or difficulty breathing) to TECFIDERA or any of its ingredients.
`
`Before taking and while you take TECFIDERA, tell your healthcare provider about any low white blood cell counts or infections or any other
`medical conditions. 
`IMPORTANT SAFETY INFORMATION AND INDICATION
`
`EXPAND
`
`https://www.tecfidera.com/en_us/home/additional-support/financial-support.html
`
`1/3
`
`MYLAN PHARMS. INC. EXHIBIT 1101 PAGE 1
`
`

`

`9/18/2019
`What are the possible side effects of TECFIDERA?
`
`Financial Support Info | Tecfidera® (dimethyl fumarate)
`
`TECFIDERA may cause serious side effects including:
`Allergic reactions
`PML, which is a rare brain infection that usually leads to death or severe disability.
`Decreases in your white blood cell count. Your healthcare provider should check your white blood cell count before you take TECFIDERA
`and from time to time during treatment
`Liver problems. Your healthcare provider should do blood tests to check your liver function before you start taking TECFIDERA and
`during treatment if needed. Tell your healthcare provider right away if you get any symptoms of a liver problem during treatment,
`including:
`severe tiredness
`loss of appetite
`pain on the right side of your stomach
`dark or brown (tea color) urine
`yellowing of your skin or the white part of your eyes
`
`The most common side effects of TECFIDERA include flushing and stomach problems. These can happen especially at the start of
`treatment and may decrease over time. Taking TECFIDERA with food may help reduce flushing. Call your healthcare provider if these
`symptoms bother you or do not go away. Ask your healthcare provider if taking aspirin before taking TECFIDERA may reduce flushing.
`
`These are not all the possible side effects of TECFIDERA. Call your healthcare provider for medical advice about side effects. You may
`report side effects to FDA at 1-800-FDA-1088. For more information go to dailymed.nlm.nih.gov.
`
`Tell your healthcare provider if you are pregnant or plan to become pregnant, or breastfeeding or plan to breastfeed. It is not known if
`TECFIDERA will harm your unborn baby or if it passes into your breast milk. Also tell your healthcare provider if you are taking prescription
`or over-the-counter medicines, vitamins, or herbal supplements. If you take too much TECFIDERA, call your healthcare provider or go to
`the nearest hospital emergency room right away.
`
`Please see full Prescribing Information and Patient Information.
`
`This is not intended to replace discussions with your healthcare provider.
`
`Indication
`Tecfidera (dimethyl fumarate) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically

`isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
`
`WHAT IS TECFIDERA?
`
`Effectiveness
`
`Safety
`
`Talking to your healthcare provider
`
`STARTING TECFIDERA
`
`Dosage
`
`Common side effects
`
`Staying on track
`
`SUPPORT & EVENTS
`
`Support program
`
`Financial & insurance information
`
`Find events
`
`What is relapsing MS?
`
`Resources for care partners
`
`PERSONAL STORIES
`
`Living with relapsing MS
`
`SIGN UP
`
`EN ESPAÑOL
`IMPORTANT SAFETY INFORMATION AND INDICATION
`
`https://www.tecfidera.com/en_us/home/additional-support/financial-support.html
`
`EXPAND
`
`2/3
`
`MYLAN PHARMS. INC. EXHIBIT 1101 PAGE 2
`
`

`

`9/18/2019
`
`Financial Support Info | Tecfidera® (dimethyl fumarate)
`
`© 2019 Biogen. All rights reserved.
`This site is intended for residents 18 years or older of the United States, Puerto Rico, and US territories.
`All trademarks are the property of their respective owners.
`
`Terms of Use
`| Privacy Policy
`| Contact Us
`| Site Map
`| Unsubscribe
`Sign Up
`
`IMPORTANT SAFETY INFORMATION AND INDICATION
`
`https://www.tecfidera.com/en_us/home/additional-support/financial-support.html
`
`EXPAND
`
`3/3
`
`MYLAN PHARMS. INC. EXHIBIT 1101 PAGE 3
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket